Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Operating Expenses (2019 - 2026)

Catalyst Pharmaceuticals filings provide 8 years of Other Operating Expenses readings, the most recent being $24.2 million for Q1 2026.

  • On a quarterly basis, Other Operating Expenses fell 11.29% to $24.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $121.7 million, a 9.01% increase, with the full-year FY2025 number at $124.8 million, up 17.44% from a year prior.
  • Other Operating Expenses hit $24.2 million in Q1 2026 for Catalyst Pharmaceuticals, down from $35.5 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $35.5 million in Q4 2025 to a low of $5.9 million in Q1 2022.
  • Median Other Operating Expenses over the past 5 years was $24.2 million (2026), compared with a mean of $22.1 million.
  • Biggest five-year swings in Other Operating Expenses: surged 179.75% in 2023 and later decreased 11.29% in 2026.
  • Catalyst Pharmaceuticals' Other Operating Expenses stood at $11.8 million in 2022, then skyrocketed by 111.19% to $24.9 million in 2023, then grew by 24.61% to $31.0 million in 2024, then grew by 14.69% to $35.5 million in 2025, then crashed by 31.97% to $24.2 million in 2026.
  • The last three reported values for Other Operating Expenses were $24.2 million (Q1 2026), $35.5 million (Q4 2025), and $32.0 million (Q3 2025) per Business Quant data.